➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Harvard Business School
Baxter
AstraZeneca
Moodys

Last Updated: March 3, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NAVITOCLAX

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for Navitoclax

Trial ID Title Status Sponsor Phase Summary
NCT00788684 Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Active, not recruiting Genentech, Inc. Phase 1 This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in subjects with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active subjects to continue to receive ABT-263 for up to 7 years after the last subject transitions with quarterly study evaluations.
NCT00788684 Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers Active, not recruiting AbbVie (prior sponsor, Abbott) Phase 1 This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in subjects with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active subjects to continue to receive ABT-263 for up to 7 years after the last subject transitions with quarterly study evaluations.
NCT00887757 Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors Completed Genentech, Inc. Phase 1 This is a Phase 1 open-label study evaluating the safety of navitoclax (ABT-263) when combined with a standard regimen of gemcitabine in approximately 50 subjects with solid tumors and measurable disease.
NCT00887757 Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors Completed Abbott Phase 1 This is a Phase 1 open-label study evaluating the safety of navitoclax (ABT-263) when combined with a standard regimen of gemcitabine in approximately 50 subjects with solid tumors and measurable disease.
NCT00891605 Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors Completed Genentech, Inc. Phase 1 Safety study of ABT-263 in Combination with Paclitaxel in Subjects with Solid Tumors.
NCT00891605 Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors Completed Abbott Phase 1 Safety study of ABT-263 in Combination with Paclitaxel in Subjects with Solid Tumors.
NCT01021358 A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). Completed Abbott Phase 1 This is a single dose, open-label, single or multiple center study to determine the interaction of ketoconazole with ABT-263 in approximately 12 subjects with cancer.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Navitoclax

Condition Name

Condition Name for
Intervention Trials
Myelofibrosis (MF) 5
Solid Tumors 4
Solid Neoplasm 3
Chronic Lymphocytic Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Primary Myelofibrosis 5
Leukemia, Lymphoid 5
Leukemia, Lymphocytic, Chronic, B-Cell 4
Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Navitoclax

Trials by Country

Trials by Country for
Location Trials
United States 87
Japan 22
Italy 9
Australia 8
Poland 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 8
New York 6
New Jersey 6
Maryland 6
Massachusetts 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Navitoclax

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 2
Phase 2 4
Phase 1/Phase 2 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Not yet recruiting 7
Completed 6
Recruiting 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Navitoclax

Sponsor Name

Sponsor Name for
Sponsor Trials
AbbVie 8
National Cancer Institute (NCI) 5
Genentech, Inc. 4
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 19
NIH 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Express Scripts
Moodys
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.